Table 1 Demographic,clinical and radiological features of the study patients when grouped according to CMB presence
All (n = 127) | CMB (−) (n = 80) | CMB (+) (n = 47) | p | |
|---|---|---|---|---|
Gender (Male) | 74 (58.3) | 49 (61.3) | 31 (38.8) | 0.374 |
Age | 66.57 ± 14.39 | 63.64 ± 15.62 | 68.45 ± 12.89 | 0.019 |
Hypertension, n(%) | 82 (64.6) | 48 (60) | 34 (72.3) | 0.16 |
Diabetes mellitus, n(%) | 43 (33.9) | 28 (35) | 15 (31.9) | 0.723 |
Hyperlipidemia, n(%) | 45 (35.4) | 28 (35) | 17 (36.2) | 0.894 |
Atrial fibrillation, n(%) | 50 (40) | 29 (37.2) | 21 (44.7) | 0.407 |
Coronary artery disease, n(%) | 25 (20) | 14 (17.5) | 11 (24.4) | 0.351 |
Previous TIA/ ischemic stroke, n(%) | 26 (20.5) | 19 (23.8) | 7 (14.9) | 0.232 |
Current antiaggregant/anticoagulant use, n(%) | 52 (40.9) | 31 (38.8) | 21 (44.7) | 0.512 |
Acute infarct location, n(%) | ||||
Anterior circulation | 77 (60.6) | 48 (60) | 29 (61.7) | 0.569 |
Posterior circulation | 44 (34.6) | 27 (33.8) | 17 (36.2) | |
Mixed location | 6 (4.7) | 5 (6.2) | 1 (2.1) | |
WMH, n(%) | < 0.001 | |||
Fazekas Grade 0 | 22 (17.3) | 20 (25) | 2 (4.3) | |
Fazekas Grade 1 | 32 (25.2) | 23 (23.8) | 9 (19.1) | |
Fazekas Grade 2 | 38 (29.9) | 23 (23.8) | 15 (31.9) | |
Fazekas Grade 3 | 35 (27.6) | 14 (17.5) | 21 (44.7) | |
Neutrophil to lymphocyte ratio | 3.32 ± 2.234 | 3.03 ± 1.72 | 3.63 ± 2.73 | 0.702 |
Mean platelet volume (fL) | 8.72 ± 1.7 | 8.73 ± 1.68 | 9.07 ± 2.11 | 0.467 |
Platelet/lymphocyte ratio | 134.74 ± 65.4 | 127.94 ± 58.5 | 146.83 ± 75.34 | 0.133 |
MPV/platelet ratio | 0.0385 ± 0.015 | 0.04 ± 0.015 | 0.0358 ± 0.013 | 0.183 |
C- reactive protein (mg/dl) | 0.3479 ± 0.324 | 0.3424 ± 0.275 | 0.3585 ± 0.41 | 0.347 |